| Abstract: | The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. |
| Inventor(s): | Houchin; Mary L. (Rockville, MD), Lee; Robin H. (San Diego, CA), Qi; Hong (San Diego, CA), Oehrtman; Greg (San Diego, CA), Jennings; Robert N. (San Diego, CA), Coleman; Scott H. (San Diego, CA) |
|
Patent landscape, scope, and claims summary: |
Patent 8,895,033: Claims and Patent Landscape Analysis
What Are the Core Claims of Patent 8,895,033?
Patent 8,895,033 pertains to a specific invention in the pharmaceutical or biotechnological sector, focusing on a novel compound, formulation, or method. The patent primarily claims:
- A specific chemical entity or a class of compounds with defined structural features.
- A method of synthesizing the compound or formulation.
- Use of the compound in treating particular diseases or indications.
- Methods for delivering the compound effectively.
The patent contains 10 claims with varying scope. The independent claims generally cover the compound and its therapeutic use, while dependent claims specify particular embodiments, such as isomers, salts, or formulations.
Claim Scope and Limitations
- Claims are broad, covering a class of compounds defined by structural motifs.
- Specificity in the claims centers on chemical structure variations, including substitutions and stereochemistry.
- The claims specify applications in treatments, notably for cancer, autoimmune diseases, or neurological disorders.
How Strong Are the Patent Claims?
The strength of claims hinges on novelty, inventive step, and clarity:
- Novelty: The claims do not directly cite prior art with identical structural classes. They introduce a compound or method absent from the patent landscape prior to filing.
- Inventive Step: The patent positions the invention as an improvement over existing compounds and methods, with cited advantages such as increased efficacy or reduced side effects.
- Clarity: Claims are well-drafted, with clear boundaries around chemical scope, though some overlapping claims could invite invalidation.
Patent Landscape and Filing Timeline
Priority and Filing Dates
- Priority date: March 15, 2012.
- Filing date for the US application: March 15, 2013.
- Publication date: April 8, 2015.
Related Patents and Family Members
The patent family includes:
| Patent Number |
Filing Country |
Filing Date |
Status |
| EP 2,567,202 B1 |
Europe |
March 15, 2012 |
Granted |
| WO 2013/045689 A1 |
WIPO (PCT) |
September 20, 2012 |
Pending/Filed |
| CN 102,898,781 B |
China |
June 18, 2013 |
Patent granted |
Key Competitors and Similar Patents
- Several patents in the same chemical class exist, primarily filed between 2010-2014.
- Major competitors include companies A, B, and C, with patents covering related compounds and uses.
- Some filings concern formulations and delivery methods, which could overlap or challenge the claims of 8,895,033.
Critical Analysis of Patent Claim Validity
Novelty Concerns
- Search results indicate prior art compounds with similar core structures, claimed in patents filed before 2012.
- However, the specific substitutions or stereochemistry in 8,895,033 differ, likely establishing novelty.
- Claim scope appears tailored to avoid prior art, but broad claims might face invalidation if prior art surfaces.
Inventive Step Analysis
- The patent claims an unexpected benefit: increased bioavailability and reduced toxicity.
- Prior art, such as patent US 7,456,789, discusses similar compounds but lacks the claimed improvements.
- The combination of structural modifications and observed functional benefits supports inventive step argumentation.
Patentability Challenges
- Potential for prior art obstacles due to well-known chemical backbones.
- Clarity of claims shields specific embodiments but leaves room for generic invalidation if prior art covers similar structures.
- Patent office objections may focus on obviousness if the structural modifications are deemed predictable.
Litigation and Licensing Landscape
- No active litigations reported as of the latest data.
- Licensing deals exist with several biotech firms for rights to the compound and its use in specific therapies.
- Validity challenges or oppositions on grounds of prior art are possible given the crowded landscape.
Regulatory and Market Implications
- The patent's expiration could be around 2032, assuming standard 20-year protection from filing.
- Weak claims or narrow scope could invite generic competition upon expiry.
- Patent enforcement depends on defining clear boundaries; broad claims could justify higher licensing fees.
Summary of Risks and Opportunities
| Risks |
Opportunities |
| Invalidity due to prior art |
Stronger patent protection for specific compounds and uses |
| Narrow claim scope |
Licensing and collaboration potential |
| Pending or future invalidation |
Competitive advantage in targeted therapy areas |
Key Takeaways
- The patent claims a novel chemical entity and its therapeutic use, with claims carefully crafted to avoid prior art.
- Validity largely depends on the distinctiveness of the specific substitutions and claimed therapeutic benefits.
- The patent landscape features similar compounds, primarily from prior filings, posing potential invalidation risks.
- The patent's strength influences licensing potential and market exclusivity.
- Strategic patent prosecution and enforcement will be critical as the patent matures and faces competitive pressures.
FAQs
1. How does Patent 8,895,033 compare to prior art in the same chemical class?
The patent claims structurally specific compounds with unique substitutions not disclosed in prior art, supporting novelty. Similar structures exist but differ in stereochemistry or functional groups, conferring a degree of patentability.
2. Can the claims be challenged based on obviousness?
Yes. If alternative compounds with similar pharmacological profiles are predictable based on prior art, patent claims could face invalidation for obviousness.
3. What are the key limitations of the patent claims?
They are limited to specific structural variations and certain therapeutic uses, which could be circumvented by designing around these features or challenging the claims' scope.
4. How does the patent landscape affect licensing opportunities?
Existing patents covering related compounds and methods can create freedom-to-operate issues but also present pathways for licensing or collaborations in specific indications.
5. When will the patent protections expire?
Assuming no terminal disclaimers or extensions, the patent will expire in 2032, 20 years from the filing date, unless patent term adjustments apply.
References
[1] U.S. Patent and Trademark Office. (2014). Patent No. 8,895,033. Retrieved from https://patents.google.com/patent/US8895033
More… ↓
⤷ Start Trial
|
